LAG3 and esophageal squamous cell carcinoma: While extensive literature documents LAG3's immunosuppressive properties and negative clinical impact [36], emerging evidence, including in ESCC contexts, suggests its paradoxical association with immune activation and improved outcomes [15, 17, 37].